Dual Contribution of Quantitative Image Analysis for the Evaluation of HER2 IHC Staining Quality, and Interpretation of HER2 Overexpression and HER2-Low Status in Breast Carcinoma

被引：0
|
作者：
Cossutta, Melissande [1 ]
Truumees, Birgit [2 ]
Papine, Alexandre [1 ]
Kristoffersen, Heidi [2 ]
Tatarinova, Ekaterina [1 ]
Homsy, Charles [1 ]
Nielsen, Soren [2 ]
Soussaline, Francoise [1 ]
机构：
[1] IMSTAR Dx, Paris, France
[2] NordiQC, Aalborg, Denmark
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
117
引用
收藏
页码：S139 / S140
页数：2
相关论文
共 50 条
  • [21] HER2 Status in Breast Carcinoma by Dual ISH in HER2 Equivocal IHC Population: Comparison Between 2013 and 2018 Guidelines in Reference Center
    De La Iglesia Niveyro, Paola
    Wernicke, Alejandra
    Pandolfi, Julieta
    Pastorutti, Ana
    Garcia-Rivello, Hernan
    LABORATORY INVESTIGATION, 2019, 99
  • [22] HER2 Status in Breast Carcinoma by Dual ISH in HER2 Equivocal IHC Population: Comparison Between 2013 and 2018 Guidelines in Reference Center
    De La Iglesia Niveyro, Paola
    Wernicke, Alejandra
    Pandolfi, Julieta
    Pastorutti, Ana
    Garcia-Rivello, Hernan
    MODERN PATHOLOGY, 2019, 32
  • [23] Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
    Marchio, Caterina
    Annaratone, Laura
    Marques, Ana
    Casorzo, Laura
    Berrino, Enrico
    Sapino, Anna
    SEMINARS IN CANCER BIOLOGY, 2021, 72 : 123 - 135
  • [24] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [25] Fluorescence quantitative image analysis of HER2 evaluation against current clinical HER2 assays in breast cancer testing
    Kornaga, E. N.
    Feng, X.
    Klimowicz, A. C.
    Dean, M. L.
    Guggisberg, N.
    Morris, D. G.
    Magliocco, A. M.
    CANCER RESEARCH, 2016, 76
  • [26] Evaluation of HER2 in Endometrial Serous Carcinomas: Is there a role for a HER2-Low Subgroup?
    Jou, David
    Hecht, Jonathan
    Quintana, Liza
    Lepe, Marcos
    LABORATORY INVESTIGATION, 2023, 103 (03) : S923 - S924
  • [27] Breast HER2 Insitu Hybridization (HER2 ISH): Acceptable and unacceptable staining criteria impacting on interpretation
    Parry, S.
    Miller, K.
    Ibrahim, M.
    VIRCHOWS ARCHIV, 2012, 461 : S258 - S258
  • [28] Her2 FISH amplification in ER/PR/Her2 IHC negative breast cancer
    Sahoo, Sunati
    Hwang, Helena
    CANCER RESEARCH, 2015, 75
  • [29] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
    Fehm, T.
    Lane, N.
    Solomayer, E.
    Wallwiener, D.
    Uhr, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
  • [30] Assessment of Reproducibility of HER2 IHC Scoring in a HER2-low Breast Cancer Enriched Cohort among Breast Subspecialized Pathologists
    Karakas, Cansu
    Tyburski, Haley
    Turner, Bradley
    Wang, Xi
    Schiffhauer, Linda
    Katerji, Hani
    Liu, Elena
    Hicks, David
    Zhang, Huina
    LABORATORY INVESTIGATION, 2023, 103 (03) : S150 - S151
12345